CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Regulation FD disclosure
- 4 Grant or award Co-Chief Executive Officer acquired 248,865 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 74,660 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 95,990 shares (grant or award)
- 4 Grant or award Co-Chief Executive Officer acquired 248,865 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 95,990 shares (grant or award)
- 4 Open-market sale Co-Chief Executive Officer sold 29,282 shares at $14.47 ($423,760)
- 4 Open-market sale Co-Chief Executive Officer sold 29,282 shares at $14.48 ($424,120)
- 4 Open-market sale Chief Medical Officer sold 6,461 shares at $14.58 ($94,205)
- 4 Open-market sale Chief Financial Officer sold 7,909 shares at $14.52 ($114,851)
- 4 Open-market sale Chief Legal Officer sold 6,844 shares at $14.52 ($99,378)
- S-8 Other Securities Offered to Employees in Benefit Plans
- S-3ASR Offering Registration Statement
Page 3 of 23 · 443 filings